Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.66 |
| ▸ | DAO | P14920 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773258 | 0.86 | DAO (0.55) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL15979699 | 0.85 | DAO (0.63) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL3752532 | 0.83 | DAO (0.61) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL26970953 | 0.82 | DAO (0.59) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL15547606 | 0.82 | DAO (0.59) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL28474265 | 0.80 | DAO (0.57) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL15979708 | 0.80 | DAO (0.52) | GSK3BDAOMAPTKDRNPSR1 | |
| SCHEMBL6789226 | 0.79 | GSK3B (1.00) | GSK3BDAO | |
| SCHEMBL6784161 | 0.79 | GSK3B (1.00) | GSK3BDAO | |
| SCHEMBL6917802 | 0.79 | DAO (0.60) | GSK3BDAONPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747057-B2 | SUCH 1-(2-BROMO-4,5-DICHLORO-THIOPHEN-3-YL)-2-CHLORO-ETHANONE FOR TREATMENT OF ALZHEIMER'S DISEASE OR DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-06-08 | — | — | US | disclosed |
| US-20030199508-A1 | Compounds and their therapeutic use | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-23 | — | — | US | disclosed |
| US-4631280-A | Pyridazine derivatives having a psychotropic action, and medicaments in which they are present | SANOFI (FR) | 1986-12-23 | — | — | US | disclosed |
| US-4565814-A | Pyridazine derivatives having a psychotropic action and compositions | SANOFI (FR) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199508-A1 | Compounds and their therapeutic use | CNKSR1, CBR1, CBR3 | GSK3B 4/4885DAO 697/4885MAPT 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.